KMT2A and leukemia: Studies demonstrating a role for histone ubiquitination in the KMT2A gene expression program, in addition to the known effect of proteasome inhibition on this mark, led us to consider the possibility that bortezomib altered the epigenetic landscape of the leukemia cells.